These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11705455)

  • 21. Increased skin tearing in broilers and reduced collagen synthesis in skin in vivo and in vitro in response to the coccidiostat halofuginone.
    Granot I; Bartov I; Plavnik I; Wax E; Hurwitz S; Pines M
    Poult Sci; 1991 Jul; 70(7):1559-63. PubMed ID: 1886867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Topically applied halofuginone, an inhibitor of collagen type I transcription, reduces peritendinous fibrous adhesions following surgery.
    Nyska M; Nyska A; Rivlin E; Porat S; Pines M; Shoshan S; Nagler A
    Connect Tissue Res; 1996; 34(2):97-103. PubMed ID: 8909874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of muscle fibrosis and improvement of muscle histopathology in dysferlin knock-out mice treated with halofuginone.
    Halevy O; Genin O; Barzilai-Tutsch H; Pima Y; Levi O; Moshe I; Pines M
    Histol Histopathol; 2013 Feb; 28(2):211-26. PubMed ID: 23275304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of glomerular mesangial cell proliferation and extracellular matrix deposition by halofuginone.
    Nagler A; Katz A; Aingorn H; Miao HQ; Condiotti R; Genina O; Pines M; Vlodavsky I
    Kidney Int; 1997 Dec; 52(6):1561-9. PubMed ID: 9407501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Growth inhibition of prostate cancer xenografts by halofuginone.
    Gavish Z; Pinthus JH; Barak V; Ramon J; Nagler A; Eshhar Z; Pines M
    Prostate; 2002 May; 51(2):73-83. PubMed ID: 11948962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Halofuginone prevents subglottic stenosis in a canine model.
    Eliashar R; Ochana M; Maly B; Pines M; Sichel JY; Nagler A
    Ann Otol Rhinol Laryngol; 2006 May; 115(5):382-6. PubMed ID: 16739671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fibrosis inhibition and muscle histopathology improvement in laminin-alpha2-deficient mice.
    Nevo Y; Halevy O; Genin O; Moshe I; Turgeman T; Harel M; Biton E; Reif S; Pines M
    Muscle Nerve; 2010 Aug; 42(2):218-29. PubMed ID: 20589893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention.
    Zion O; Genin O; Kawada N; Yoshizato K; Roffe S; Nagler A; Iovanna JL; Halevy O; Pines M
    Pancreas; 2009 May; 38(4):427-35. PubMed ID: 19188864
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of Wilms tumor xenograft progression by halofuginone is accompanied by activation of WT-1 gene expression.
    Pinthus JH; Sheffer Y; Nagler A; Fridman E; Mor Y; Genina O; Pines M
    J Urol; 2005 Oct; 174(4 Pt 2):1527-31. PubMed ID: 16148645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduction in pulmonary fibrosis in vivo by halofuginone.
    Nagler A; Firman N; Feferman R; Cotev S; Pines M; Shoshan S
    Am J Respir Crit Care Med; 1996 Oct; 154(4 Pt 1):1082-6. PubMed ID: 8887611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Halofuginone inhibits tumor growth in the polyoma middle T antigen mouse via a thrombospondin-1 independent mechanism.
    Yee KO; Connolly CM; Pines M; Lawler J
    Cancer Biol Ther; 2006 Feb; 5(2):218-24. PubMed ID: 16418571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo.
    Gross DJ; Reibstein I; Weiss L; Slavin S; Dafni H; Neeman M; Pines M; Nagler A
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3788-93. PubMed ID: 14506172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Halofuginone inhibits serum-stimulated pericardial tissue retraction in vitro.
    Marchion DC; Weber PA; Lomnitski L; Duran CM; Cheung DT
    Tissue Eng; 2004; 10(7-8):1076-83. PubMed ID: 15363165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of halofuginone, a specific inhibitor of collagen type 1 synthesis, in the prevention of pancreatic fibrosis in an experimental model of severe hyperstimulation and obstruction pancreatitis.
    Karatas A; Paksoy M; Erzin Y; Carkman S; Gonenc M; Ayan F; Aydogan F; Uzun H; Durak H
    J Surg Res; 2008 Jul; 148(1):7-12. PubMed ID: 18570924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone.
    Elkin M; Reich R; Nagler A; Aingorn E; Pines M; de-Groot N; Hochberg A; Vlodavsky I
    Clin Cancer Res; 1999 Aug; 5(8):1982-8. PubMed ID: 10473075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Halofuginone inhibits NF-kappaB and p38 MAPK in activated T cells.
    Leiba M; Cahalon L; Shimoni A; Lider O; Zanin-Zhorov A; Hecht I; Sela U; Vlodavsky I; Nagler A
    J Leukoc Biol; 2006 Aug; 80(2):399-406. PubMed ID: 16769768
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone.
    Turgeman T; Hagai Y; Huebner K; Jassal DS; Anderson JE; Genin O; Nagler A; Halevy O; Pines M
    Neuromuscul Disord; 2008 Nov; 18(11):857-68. PubMed ID: 18672370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Halofuginone reduces the occurrence of renal fibrosis in 5/6 nephrectomized rats.
    Benchetrit S; Yarkoni S; Rathaus M; Pines M; Rashid G; Bernheim J; Bernheim J
    Isr Med Assoc J; 2007 Jan; 9(1):30-4. PubMed ID: 17274353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma.
    Ong C; Wong C; Roberts CR; Teh HS; Jirik FR
    Eur J Immunol; 1998 Sep; 28(9):2619-29. PubMed ID: 9754550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of rat renal fibroblast proliferation by halofuginone.
    Haran N; Leschinski L; Pines M; Rapoport J
    Nephron Exp Nephrol; 2006; 104(1):e35-40. PubMed ID: 16735800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.